Clinical trial · Observational
Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine
Development of Pancreatic Cancer Diagnostic Method by Using a Reagent for Analyzing Purine Metabolite (Hypoxanthine, Xanthine) in Urine
NCT06291779CI-TRIAL-00074638unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine. * It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diagnosis | — | UNRESOLVED | — |
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Pancreatic cancer group
- description
- scheduled for curative surgery for pancreatic cancer
- interventionNames
- Device: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
- label
- Control group
- description
- group included healthy individuals as well as patients with benign diseases
- interventionNames
- Device: Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
Primary outcomes (1)
- measure
- Urine
- timeFrame
- 1 day
- description
- mean concentration of purine metabolites in urine
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
1. pancreatic cancer group Inclusion Criteria: * Pancreatic ductal adenocarcinoma that is pathologically confirmed or shows characteristic radiologic features * Patients with resectable pancreatic cancer at the time of surgery (Including borderline resectable pancreatic cancer at the time of diagnosis or Locally advanced pancreatic cancer after chemotherapy or radiation therapy) * Patients without invasion of adjacent organs other than the left adrenal gland and mesocolon * Patients with informed consent Exclusion Criteria: * History of other malignancy (Inclusive if there is no evidence of recurrence after 5 years of treatment) * Patient with Inflammatory disease(e.g. severe pancreatitis, cholangitis) * Patients with underlying diseases at high risk of general anesthesia * Other subject whom the investigator deems inappropriate 2. control group Inclusion Criteria included healthy individuals as well as patients with benign diseases. Exclusion criteria for the control group included a previous cancer diagnosis within the past five years, active inflammatory diseases, borderline malignant pancreatic tumors, or a postoperative pathological finding of malignancy.
References
Publications (1)
- BACKGROUNDWu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta. 2009 Aug 19;648(1):98-104. doi: 10.1016/j.aca.2009.06.033. Epub 2009 Jun 21. PMID 19616694